Low risk of herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent genital herpes simplex virus infections
CG Prober, WM Sullender, LL Yasukawa, DS Au, AS Yeager, and AM Arvin
We studied the risk of herpes simplex virus (HSV) infections in neonates exposed to HSV at the time of vaginal delivery to mothers with a history of recurrent genital HSV infections. None of 34 infants exposed to HSV type 2 acquired an HSV infection. On the basis of this sample, the 95 percent confidence limit for the theoretical maximum infection rate is 8 percent. Cord blood or blood obtained during the first two weeks of life was available from 33 of the 34 exposed, uninfected neonates. All 33 of the samples possessed demonstrable neutralizing antibody to HSV type 2, and 79 percent had titers above 1:20. These results were compared with those in a previously studied group of neonates with HSV infections; the latter infants were significantly less likely at the onset of symptoms to have demonstrable neutralizing antibody to HSV type 2 (P = 0.000148) or to have titers above 1:20 (P less than 0.00001). We conclude that given the low attack rate, empirical antiviral therapy is not warranted in all infants of mothers with recurrent genital HSV infection who are exposed to the virus in the birth canal. Our findings suggest that the presence and titer of neutralizing antibody to HSV contribute to the low attack rate.
This article has been cited by other articles:
Kimberlin, D. W.
(2004). Neonatal Herpes Simplex Infection. Clin. Microbiol. Rev.
17: 1-13
[Abstract][Full Text]
Fisman, D N, Hook, E W III, Goldie, S J
(2003). Estimating the costs and benefits of screening monogamous, heterosexual couples for unrecognised infection with herpes simplex virus type 2. Sex. Transm. Infect.
79: 45-52
[Abstract][Full Text]
Corey, L., Handsfield, H. H.
(2000). Genital Herpes and Public Health: Addressing a Global Problem. JAMA
283: 791-794
[Abstract][Full Text]
Corey, L., Langenberg, A. G. M., Ashley, R., Sekulovich, R. E., Izu, A. E., Douglas, J. M. Jr, Handsfield, H. H., Warren, T., Marr, L., Tyring, S., DiCarlo, R., Adimora, A. A., Leone, P., Dekker, C. L., Burke, R. L., Leong, W. P., Straus, S. E., for the Chiron HSV Vaccine Study Group,
(1999). Recombinant Glycoprotein Vaccine for the Prevention of Genital HSV-2 Infection: Two Randomized Controlled Trials. JAMA
282: 331-340
[Abstract][Full Text]
Mikloska, Z., Sanna, P. P., Cunningham, A. L.
(1999). Neutralizing Antibodies Inhibit Axonal Spread of Herpes Simplex Virus Type 1 to Epidermal Cells In Vitro. J. Virol.
73: 5934-5944
[Abstract][Full Text]
De Logu, A., Williamson, R. A., Rozenshteyn, R., Ramiro-Ibañez, F., Simpson, C. D., Burton, D. R., Paolo Sanna, P.
(1998). Characterization of a Type-Common Human Recombinant Monoclonal Antibody to Herpes Simplex Virus with High Therapeutic Potential. J. Clin. Microbiol.
36: 3198-3204
[Abstract][Full Text]
King, C. L., Malhotra, I., Mungai, P., Wamachi, A., Kioko, J., Ouma, J. H., Kazura, J. W.
(1998). B Cell Sensitization to Helminthic Infection Develops In Utero in Humans. J. Immunol.
160: 3578-3584
[Abstract][Full Text]
Arvin, A. M., Prober, C. G.
(1997). Herpes Simplex Virus Type 2 -- A Persistent Problem. NEJM
337: 1158-1159
[Full Text]
Previous
